2024-10-19 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and manufactures a wide range of medicines, including treatments for diabetes, cancer, and autoimmune diseases. 

**1. Performance Comparison:**

* **Cumulative Return:** LLY (883.86) significantly outperformed the S&P 500 (VOO, 136.97).
* **Performance Gap:** The current gap between LLY and VOO is 746.89, representing 92.67% of the historical performance gap range. This indicates that LLY has consistently outperformed VOO over a historical period.

**2. Recent Price Action:**

* **Closing Price:** $917.12
* **5-Day Moving Average:** $921.69
* **20-Day Moving Average:** $907.96
* **60-Day Moving Average:** $898.56

The current price is slightly below the 5-day moving average, suggesting potential short-term weakness. However, it's trading above the 20-day and 60-day moving averages, implying a longer-term upward trend.

**3. Technical Indicators:**

* **RSI:** 66.67 - Indicates the stock is in overbought territory, potentially suggesting a near-term correction.
* **PPO:** 0.24 - A positive value suggests an upward momentum, but it's not extremely high, indicating a gradual upward trend.
* **Delta_Previous_Relative_Divergence:**  0.49 (-) - This suggests a recent slight decrease in relative performance compared to the market.
* **Expected Return:** 35.02% - This represents the potential 5-year expected return, exceeding the S&P 500 (VOO) by a significant margin.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings report shows an EPS of 3.29, exceeding analyst estimates. Revenue also surpassed expectations. The company continues to demonstrate strong growth in its core business, particularly in diabetes and cancer treatments.

**5. News and Recent Events:**

* **Recent Market Outlook:**  LLY has been a strong performer in recent quarters, driven by its robust drug pipeline and a positive outlook on the pharmaceutical industry.  
* **Analyst Opinions:**  Most analysts remain optimistic about LLY's long-term prospects. They cite its strong financial position, innovative product portfolio, and a growing market for its medications. 
* **Performance Highlights:**  Recent positive performance is driven by the strong sales of several key drugs like Mounjaro (for diabetes) and Verzenio (for breast cancer). 

**6. Summary:**

LLY is a strong performer with a solid track record of outperforming the market. Its recent earnings beat and continued growth in key segments suggest ongoing positive momentum. However, the current RSI suggests potential short-term weakness, which could lead to a pullback. Despite this, LLY remains a fundamentally strong company with a positive outlook, backed by a strong product pipeline and a growing market for its medications. The high expected return further strengthens its potential as a long-term investment.

**7. Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is crucial to conduct thorough research and consult with a financial professional before making any investment decisions.